|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Third-line rescue therapy for Helicobacter pylori infection显示文摘H pylori 胃的感染是世界范围的最流行的传染病之一。很上面的胃肠的疾病与 H pylori 感染有关能因此与抗菌素被对待的发现是重要医药进展。当前,首要的三倍的治疗被所有一致会议和指南基于质子泵禁止者(PPI ) 或加二抗菌素(clarithromycin 和 amoxicillin 或 nitroimidazole ) 的 ranitidine 枸橼酸铋(RBC ) 推荐。甚至与这药联合的正确使用,感染不能在多达 23% 病人被根除。因此,几第二线治疗被推荐了。7 d 四倍的治疗基于 PPI,铋,四圜素和灭滴灵,更多经常被接受。与第二线的治疗,然而,细菌的根除可以在多达 40% 盒子失败。当 H pylori 根除严格地被显示时,进一步的治疗的选择是争论的。当前,标准第三线的治疗正在缺乏,各种各样的协议被建议了。甚至在二连续失败以后,最近的文学数据证明了 H pylori 根除能在几乎所有病人被完成,甚至当抗菌素危险性没被测试时。实验治疗的不同可能性存在,可得到的第三线的策略此处被考察。 | Rossella Cianci Massimo Montalto Franco Pandolfi Giovan Battista Gasbarrini Giovanni Cammarota | 2006 | World Journal of Gastroenterology2006，12，15： | 31 |
| 2 | Extraintestinal manifestations in inflammatory bowel disease显示文摘Inflammatory bowel diseases (IBD) can be really considered to be systemic diseases since they are often associated with extraintestinal manifestations,complications, and other autoimmune disorders. Indeed,physicians who care for patients with ulcerative colitis and Crohn's disease, the two major forms of IBD, face a new clinical challenge every day, worsened by the very frequent rate of extraintestinal complications. The goal of this review is to provide an overview and an update on the extraintestinal complications occurring in IBD.Indeed, this paper highlights how virtually almost every organ system can be involved, principally eyes, skin,joints, kidneys, liver and biliary tracts, and vasculature (or vascular system) are the most common sites of systemic IBD and their involvement is dependent on different mechanisms. | Silvio Danese Stefano Semeraro Alfredo Papa Italia Roberto Franco Scaldaferri Giuseppe Fedeli Giovanni Gasbarrini Antonio Gasbarrini | 2005 | World Journal of Gastroenterology2005，11，46： | 24 |
| 3 | Gut microbiota in autism and mood disorders显示文摘The hypothesis of an important role of gut microbiota in the maintenance of physiological state into the gastrointestinal(GI)system is supported by several studies that have shown a qualitative and quantitative alteration of the intestinal flora in a number of gastrointestinal and extra-gastrointestinal diseases.In the last few years,the importance of gut microbiota impairment in the etiopathogenesis of pathology such as autism,dementia and mood disorder,has been raised.The evidence of the inflammatory state alteration,highlighted in disorders such as schizophrenia,major depressive disorder and bipolar disorder,strongly recalls the microbiota alteration,highly suggesting an important role of the alteration of GI system also in neuropsychiatric disorders.Up to now,available evidences display that the impairment of gut microbiota plays a key role in the development of autism and mood disorders.The application of therapeutic modulators of gut microbiota to autism and mood disorders has been experienced only in experimental settings to date,with few but promising results.A deeper assessment of the role of gut microbiota in the development of autism spectrum disorder(ASD),as well as the advancement of the therapeutic armamentarium for the modulation of gut microbiota is warranted for a better management of ASD and mood disorders. | Francesca Mangiola Gianluca Ianiro Francesco Franceschi Stefano Fagiuoli Giovanni Gasbarrini Antonio Gasbarrini | 2016 | World Journal of Gastroenterology2016，22，1： | 23 |
| 4 | Role and mechanisms of action of escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update显示文摘Ulcerative colitis(UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the 'forgotten organ', Gut Microbiota. Several studies have been conducted to assess the role of antibiotics and probiotics as additional or alternative therapies for Ulcerative Colitis. Escherichia coli Nissle(Ec N) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor®(Ardeypharm Gmb H, Herdecke, Germany and Ec N, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine in maintenance of remission in UC patients. In this review we propose an update on the role of Ec N 1917 in maintenance of remission in UC patients, including data about efficacy and safety. Further studies may be helpful for this subject to further the full use of potential of Ec N. | Franco Scaldaferri Viviana Gerardi Francesca Mangiola Loris Riccardo Lopetuso Marco Pizzoferrato Valentina Petito Alfredo Papa Jovana Stojanovic Andrea Poscia Giovanni Cammarota Antonio Gasbarrini | 2016 | World Journal of Gastroenterology2016，22，24： | 19 |
| 5 | Evaluation of thermal water in patients with functional dyspepsia and irritable bowel syndrome accompanying constipation显示文摘瞄准:与机能性消化不良或伴随占优势的便秘的急躁的肠症候群(IBS ) 在病人评估水补充治疗的功效。方法:有机能性消化不良的 3872 个病人和有急躁的肠症候群的 3609 个病人的一个总数被 18 个 Italina 热中心在学习注册。病人们为 21 d 经历了热治疗的第一个周期。一年以后,病人们在一样的中心被重新估计并且收到了热治疗的另一个周期。在社会、职业的地位,家庭和病理学的病历,生活方式,临床的记录,福利的利用和健康结构和设备上收集个人数据的一张问询表在各热的治疗以后在基础时间和一年予每个病人被以。有机能性消化不良的六十个病人并且 20 由呼吸测试分析与 IBS 和 80 健康控制收到了胃的输出和 oro 盲肠的运输时间的评估。呼吸测试在基础时间并且在水补充治疗以后被执行。胃肠的症状同时被评估点。呼吸样品与集体 spectometer 和 gascromatograph 被分析。结果为呼吸测试的 octanoic 和 lactulose 呼吸测试的同样 oro 盲肠的运输时间被表示为 T (1/2 ) 和 T 落后。结果:症状的流行的重要减小在热治疗的第一和第二个周期的结束被观察在消化不良并且 IBS 病人。变化的分析出现了一真实并且在所有病人坚持症状的蚂蚁改进。在为 3 wk 的水补充以后,胃的输出的减小在 49 被观察(87.5%) 56 个消化不良的病人。T (1/2 ) 和 T 落后显著地与基础价值相比在治疗以后被减少[91 +/- 12 T (1/2 ) 和 53 +/- 11 (T 落后) ,搁置 1 和 2 ] 与类似于健康题目的 octanoic 呼吸测试的结果。在为 3 wk 的水补充以后, oro 盲肠的运输时间在学习的开始是比那短的。结论:为伴随 IBS 的机能性消化不良或便秘的矿水补充治疗能改进胃的酸输出和肠的运输时间。 | Giovanni Gasbarrini Marcello Candelli RiccardoGiuseppe Graziosetto Sergio Coccheri Ferdinando Di Iorio Giuseppe Nappi | 2006 | World Journal of Gastroenterology2006，12，16： | 12 |
| 6 | Management and treatment of lactose malabsorption显示文摘乳糖吸收不良是肠的乳糖酶缺乏描绘的一个很普通的条件。主要乳糖吸收不良是在世界的人口的多数在场的继承赤字,当第二等的 hypolactasia 能是肠的疾病的后果时。在结肠的腔的 malabsorbed 乳糖的存在引起胃肠的症状。条件作为乳糖不耐被知道。在有乳糖酶的病人非坚持,如果不耐症状是在场的,治疗应该只被考虑。当指南不在时,普通治疗学的途径趋于从食谱排除牛奶和奶店产品。然而,这策略可以有严肃的营养的劣势。几研究被执行了发现其他的途径,例如为他们的细菌的乳糖酶活动的外长的贝它牛乳糖,酸乳酪和职业人员生命学,药理学、非药理学能延长的策略联系在推迟胃肠的运输时间,和长期的乳糖摄取提高结肠的改编的酶和底层之间的时间。在这评论,这些途径的实用性被讨论,有一份流动图表的一个治疗学的管理被建议。 | Massimo Montalto Valentina Curigliano Luca Santoro Monica Vastola Giovanni Cammarota Raffaele Manna Antonio Gasbarrini Giovanni Gasbarrini | 2006 | World Journal of Gastroenterology2006，12，2： | 12 |
| 7 | Endoscopic tools for the diagnosis and evaluation of celiac disease显示文摘Celiac disease(CD)is an autoimmune disease of the small bowel induced by ingestion of wheat,rye and barley.Current guidelines indicate histological analysis on at least four duodenal biopsies as the only way to diagnose CD.These indications are based on the conception of the inability of standard endoscopy to make diagnosis of CD and/or to drive biopsy sampling.Over the last years,technology development of endoscopic devices has greatly ameliorated the accuracy of macroscopic evaluation of duodenal villous pattern,increasing the diagnostic power of endoscopy of CD.The aim of this paper is to review the new endoscopic tools and procedures proved to be useful in the diagnosis of CD,such as chromoendoscopy,Fujinon Intelligent Chromo Endoscopy,Narrow Band Imaging,Optical Coherence Tomography,Water-Immersion Technique,confocal laser endomicroscopy,high-resolution magnification endoscopy,capsule endoscopy and I-Scan technology. | Gianluca Ianiro Antonio Gasbarrini Giovanni Cammarota | 2013 | World Journal of Gastroenterology2013，19，46： | 5 |
| 8 | Colon cancer stem cells:Controversies and perspectives显示文摘Tumors have long been viewed as a population in which all cells have the equal propensity to form new tumors,the so called conventional stochastic model.The cutting-edge theory on tumor origin and progression,tends to consider cancer as a stem cell disease.Stem cells are actively involved in the onset and maintenance of colon cancer.This review is intended to examine the state of the art on colon cancer stem cells(CSCs),with regard to the recent achievements of basic research and to the corresponding translational consequences.Specific prominence is given to the hypothesized origin of CSCs and to the methods for their identification.The growing understanding of CSC biology is driving the optimization of novel anti-cancer targeted drugs. | Maria Ausiliatrice Puglisi Valentina Tesori Wanda Lattanzi Giovanni Battista Gasbarrini Antonio Gasbarrini | 2013 | World Journal of Gastroenterology2013，19，20： | 5 |
| 9 | Microscopic colitis显示文摘Microscopic colitis may be defined as a clinical syndrome, of unknown etiology, consisting of chronic watery diarrhea, with no alterations in the large bowel at the endoscopic and radiologic evaluation. Therefore, a definitive diagnosis is only possible by histological analysis. The epidemiological impact of this disease has become increasingly clear in the last years, with most data coming from Western countries. Microscopic colitis includes two histological subtypes [collagenous colitis (CC) and lymphocytic colitis (LC)] with no differences in clinical presentation and management. Collagenous colitis is characterized by a thickening of the subepithelial collagen layer that is absent in LC. The main feature of LC is an increase of the density of intra-epithelial lymphocytes in the surface epithelium. A number of pathogenetic theories have been proposed over the years, involving the role of luminal agents, autoimmunity, eosinophils, genetics (human leukocyte antigen), biliary acids, infections, alterations of pericryptal fibroblasts, and drug intake; drugs like ticlopidine, carbamazepine or ranitidine are especially associated with the development of LC, while CC is more frequently linked to cimetidine, non-steroidal antiinflammatory drugs and lansoprazole. Microscopic colitis typically presents as chronic or intermittent watery diarrhea, that may be accompanied by symptoms such as abdominal pain, weight loss and incontinence. Recent evidence has added new pharmacological options for the treatment of microscopic colitis:the role of steroidal therapy, especially oral budesonide, has gained relevance, as well as immunosuppressive agents such as azathioprine and 6-mercaptopurine. The use of anti-tumor necrosis factoragents, infliximab and adalimumab, constitutes a new, interesting tool for the treatment of microscopic colitis, but larger, adequately designed studies are needed to confirm existing data. | Gianluca Ianiro Giovanni Cammarota Luca Valerio Brigida Eleonora Annicchiarico Alessandro Milani Massimo Siciliano Antonio Gasbarrini | 2012 | World Journal of Gastroenterology2012，18，43： | 4 |
| 10 | Culture-guided treatment approach for Helicobacter pylori infection:Review of the literature显示文摘The progressive loss of efficacy of standard eradication therapies has made the treatment of Helicobacter pylori(H.pylori)more challenging than ever.Endoscopicguided antibiotic susceptibility testing had previously been suggested to guide treatment after failure of second-line therapies.However,its role has expanded over the years,in accordance with the current Maastricht Guidelines.Several authors have dealt with this topic,developing both efficacy trials and cost-effectiveness trials against resistant H.pylori infections as well as infections in nave patients.However,results are not homogeneous enough to provide definite advice,because antibiotic resistance is not the only reason for treatment failure.Moreover,the culture-guided approach is surrounded by many practical issues,such as the availability of both endoscopy units and microbiology laboratories,and the need for a standard of quality that cannot be satisfied everywhere.Finally,pre-treatment susceptibility testing should be partand not the only weapon-of a targeted,personalized strategy to overcome H.pylori infection. | Giovanni Cammarota Gianluca Ianiro Stefano Bibbò Teresa Antonella Di Rienzo Luca Masucci Maurizio Sanguinetti Antonio Gasbarrini | 2014 | World Journal of Gastroenterology2014，20，18： | 3 |
| 11 | Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant Helicobacter pylori : A Clinical Trial显示文摘 | Giovanni Cammarota Giovanna Branca Fausta Ardito Maurizio Sanguinetti Gianluca Ianiro Rossella Cianci Riccardo Torelli Giovanna Masala Antonio Gasbarrini Giovanni Fadda Raffaele Landolfi Giovanni Gasbarrini | 2010 | Clinical Gastroenterology and Hepatology2010，，9： | 3 |
| 12 | Actual concept of 'probiotics':Is it more functional to science or business?显示文摘It is our contention that the concept of a probiotic as a living bacterium providing unspecified health benefits is inhibiting the development and establishment of an evidence base for the growing field of pharmacobiotics.We believe this is due in part to the current regulatory framework,lack of a clear definition of a probiotic,the ease with which currently defined probiotics can be positioned in the market place,and the enormous profits earned for minimum investment in research.To avoid this,we believe the following two actions are mandatory:international guidelines by a forum of stakeholders made available to scientists and clinicians,patient organizations,and governments;public research funds made available to the scientific community for performing independent rigorous studies both at the preclinical and clinical levels. | Michele Caselli Francesca Cassol Girolamo Calò John Holton Giovanni Zuliani Antonio Gasbarrini | 2013 | World Journal of Gastroenterology2013，19，10： | 3 |
| 13 | Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?显示文摘AIM To evaluate the prevalence of nodular lymphoid hyperplasia(NLH) in adult patients undergoing colonoscopy and its association with known diseases. METHODS We selected all cases showing NLH at colonoscopy in a three-year timeframe, and stratified them into symptomatic patients with irritable bowel syndrome(IBS)-type symptoms or suspected inflammatory bowel disease(IBD), and asymptomatic individuals undergoing endoscopy for colorectal cancer screening.Data collection included medical history and final diagnosis. As controls, we considered all colonoscopies performed for the aforementioned indications during the same period.RESULTS One thousand and one hundred fifty colonoscopies were selected. NLH was rare in asymptomatic individuals(only 3%), while it was significantly more prevalent in symptomatic cases(32%). Among organic conditions associated with NLH, the most frequent was IBD, followed by infections and diverticular disease. Interestingly, 31% of IBS patients presented diffuse colonic NLH. NLH cases shared some distinctive clinical features among IBS patients: they were younger, more often female, and had a higher frequency of abdominal pain, bloating, diarrhoea, unspecific inflammation, self-reported lactose intolerance and metal contact dermatitis. CONCLUSION About 1/3 of patients with IBS-type symptoms or suspected IBD presented diffuse colonic NLH, which could be a marker of low-grade inflammation in a conspicuous subset of IBS patients. | Anna Chiara Piscaglia Lucrezia Laterza Valentina Cesario Viviana Gerardi Rosario Landi Loris Riccardo Lopetuso Giovanni Calò Giovanna Fabbretti Massimo Brisigotti Maria Loredana Stefanelli Antonio Gasbarrini | 2016 | World Journal of Gastroenterology2016，22，46： | 2 |
| 14 | The Water Immersion Technique is Easy to Learn for Routine Use During EGD for Duodenal Villous Evaluation: A Single-Center 2-year Experience显示文摘 | Giovanni Cammarota Paola Cesaro Alessia Cazzato Rossella Cianci Paolo Fedeli Veronica Ojetti Maria Certo Lucia Sparano Silvia Giovannini Luigi M. Larocca Fabio M. Vecchio Giovanni Gasbarrini | 2009 | Journal of Clinical Gastroenterology2009，，3： | 2 |
| 15 | Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center显示文摘 | Giovanni Addolorato Antonio Mirijello Lorenzo Leggio Anna Ferrulli Cristina D’Angelo Gabriele Vassallo Anthony Cossari Giovanni Gasbarrini Raffaele Landolfi Salvatore Agnes Antonio Gasbarrini | 2013 | Alcohol Clin Exp Res2013，，9： | 2 |
| 16 | Antibodies Anti‐Caga Cross‐React with Trophoblast Cells: A Risk Factor for Pre‐Eclampsia?显示文摘 | Francesco Franceschi Nicoletta Di Simone Silvia D’Ippolito Roberta Castellani Fiorella Di Nicuolo Giovanni Gasbarrini Yoshio Yamaoka Tullia Todros Giovanni Scambia Antonio Gasbarrini | 2012 | Helicobacter2012，，6： | 2 |
| 17 | Water-immersion Technique During Standard Upper Endoscopy May Be Useful to Drive the Biopsy Sampling of Duodenal Mucosa in Children With Celiac Disease显示文摘 | Giovanni Cammarota Alessia Cazzato Orazio Genovese Adriano Pantanella Gianluca Ianiro Valentina Giorgio Massimo Montalto Fabio M Vecchio Luigi M Larocca Giovanni Gasbarrini Carlo Fundarò | 2009 | Journal of Pediatric Gastroenterology and Nutrition2009，，4： | 2 |
| 18 | Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease显示文摘 | Luca Miele Venanzio Valenza Giuseppe La Torre Massimo Montalto Giovanni Cammarota Riccardo Ricci Roberta Mascianà Alessandra Forgione Maria L. Gabrieli Germano Perotti Fabio M. Vecchio Gianlodovico Rapaccini Giovanni Gasbarrini Chris P. Day Antonio Grieco | 2009 | Hepatology2009，，6： | 2 |
| 19 | Effect of different probiotic preparations on anti- Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study显示文摘 | Filippo Cremonini Simona Di Caro Marcello Covino Alessandro Armuzzi Maurizio Gabrielli Luca Santarelli Enrico C Nista Giovanni Cammarota Giovanni Gasbarrini Antonio Gasbarrini | 2002 | The American Journal of Gastroenterology2002，，11： | 2 |
| 20 | Lack of endoscopic visualization of intestinal villi with the “immersion technique” in overt atrophic celiac disease显示文摘 | Antonio Gasbarrini Veronica Ojetti Lucio Cuoco Giovanni Cammarota Alessio Migneco Alessandro Armuzzi Paolo Pola Giovanni Gasbarrini | 2003 | Gastrointestinal Endoscopy2003，，3： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员